Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera, Inc. (NASDAQ: NTRA) has filed a patent infringement lawsuit against Progenity, Inc. in the U.S. District Court for the Western District of Texas. The suit claims that Progenity's non-invasive prenatal test infringes on six patents held by Natera. These include U.S. Patents 9,228,234; 9,424,392; 10,227,652; 10,240,202; 10,266,893; and 10,522,242. Natera is seeking both injunctive relief and monetary damages.